Table 1

Main tumor agnostic/biomarker driven clinical trials based on NGS analysis active in Italy (December 2021)

Trial name	Molecular driver	Targeted agent	Study design	Population
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (NCT04589845)	ROS1 fusions NTRK1/2/3 fusion ALK fusion TMB high AKT1/2/3 mutation HER2 mutation MDM2-amplified, TP53 wild-type PIK3CA mutation BRAF class II–III mutations RET fusion	Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emtansine Idasanutlin Inavolisib Belvarafenib Pralsetinib	Phase II, multicohort	Advanced solid tumors
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (NCT04931342)	PTEN loss of function mutations AKT1/2/3 mutation PIK3CA mutation ERBB2 mutation or amplification	Ipatasertib Cobimetinib Trastuzumab emtansine Atezolizumab Bevacizumab Paclitaxel	Phase II, multicohort	Persistent or recurrent rare epithelial ovarian cancers
Safety and Efficacy of Retifanlimab alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204) (NCT04463771)	MSI high TMB high POLE mutations FGFR 1,2,3 mutation or alteration	Retifanlimab Epacadostat Pemigatinib	Phase II, multicohort	Advanced or metastatic endometrial cancer
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (NCT04083976)	FGFR gene alterations	Erdafitinib	Phase II, single cohort	Advanced solid tumor
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) (NCT04591431)	EGFR mutation ERBB2 amplification or mutation mTOR mutation AKT mutation BRAF V600E mutation CDK 4/6 mutation CDKN2A mutation BCR-ABL gene fusion SMO/PTCH1 mutation JAK mutation FGFR 1-2-3 gene alterations PI3KCA, AKT, PTEN mutations NTRK 1-2-3 fusion ROS1 fusion MSI high TMB high	Erlotinib Trastuzumab Trastuzumab emtansine Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib	Randomized, phase II	Advanced solid tumor

NGS, next generation sequencing .